Stem definition | Drug id | CAS RN |
---|---|---|
bradykinin receptors antagonists | 4186 | 130308-48-4 |
Dose | Unit | Route |
---|---|---|
30 | mg | P |
None
Date | Agency | Company | Orphan |
---|---|---|---|
Sept. 21, 2018 | PMDA | Shire Japan KK | |
July 11, 2008 | EMA | Shire Pharmaceuticals Ireland Limited | |
Aug. 25, 2011 | FDA | SHIRE ORPHAN THERAP |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hereditary angioedema | 1683.60 | 32.19 | 293 | 3061 | 5149 | 50596621 |
Pharyngeal oedema | 242.94 | 32.19 | 71 | 3283 | 13094 | 50588676 |
Prescribed overdose | 210.06 | 32.19 | 65 | 3289 | 14535 | 50587235 |
Laryngeal oedema | 195.99 | 32.19 | 49 | 3305 | 5004 | 50596766 |
Inappropriate schedule of product administration | 168.63 | 32.19 | 86 | 3268 | 71745 | 50530025 |
No adverse event | 111.31 | 32.19 | 51 | 3303 | 33527 | 50568243 |
Injection site pain | 91.12 | 32.19 | 68 | 3286 | 110956 | 50490814 |
Product availability issue | 69.81 | 32.19 | 18 | 3336 | 2070 | 50599700 |
Swollen tongue | 60.44 | 32.19 | 32 | 3322 | 28598 | 50573172 |
Localised oedema | 50.76 | 32.19 | 17 | 3337 | 4850 | 50596920 |
Hospitalisation | 49.88 | 32.19 | 39 | 3315 | 67898 | 50533872 |
Device related infection | 46.09 | 32.19 | 24 | 3330 | 20711 | 50581059 |
Product dose omission issue | 45.00 | 32.19 | 58 | 3296 | 183780 | 50417990 |
Injection site erythema | 40.42 | 32.19 | 36 | 3318 | 74900 | 50526870 |
Poor venous access | 38.31 | 32.19 | 17 | 3337 | 10323 | 50591447 |
Pharyngeal swelling | 36.21 | 32.19 | 13 | 3341 | 4553 | 50597217 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hereditary angioedema | 595.23 | 46.29 | 80 | 632 | 681 | 29573134 |
Inappropriate schedule of product administration | 55.24 | 46.29 | 25 | 687 | 44447 | 29529368 |
Injection site pain | 52.54 | 46.29 | 22 | 690 | 32424 | 29541391 |
MedDRA adverse event term | Likelihood ratio | Likelihood ratio threshold | Patients taking drug having adverse event | Patients taking drug not having adverse event | Patients not taking drug having adverse event | Patients not taking drug not having adverse event |
---|---|---|---|---|---|---|
Hereditary angioedema | 1510.17 | 35.43 | 239 | 2520 | 3637 | 64492336 |
Pharyngeal oedema | 225.16 | 35.43 | 63 | 2696 | 15468 | 64480505 |
Laryngeal oedema | 155.74 | 35.43 | 40 | 2719 | 7073 | 64488900 |
Inappropriate schedule of product administration | 138.93 | 35.43 | 71 | 2688 | 92215 | 64403758 |
Prescribed overdose | 133.81 | 35.43 | 45 | 2714 | 20286 | 64475687 |
Injection site pain | 112.92 | 35.43 | 66 | 2693 | 111342 | 64384631 |
No adverse event | 90.65 | 35.43 | 37 | 2722 | 28524 | 64467449 |
Localised oedema | 68.08 | 35.43 | 21 | 2738 | 7170 | 64488803 |
Product dose omission issue | 63.33 | 35.43 | 58 | 2701 | 194689 | 64301284 |
Product availability issue | 61.79 | 35.43 | 15 | 2744 | 2101 | 64493872 |
Swollen tongue | 61.61 | 35.43 | 30 | 2729 | 34924 | 64461049 |
Injection site erythema | 46.63 | 35.43 | 32 | 2727 | 70768 | 64425205 |
Hospitalisation | 40.33 | 35.43 | 30 | 2729 | 75177 | 64420796 |
None
Source | Code | Description |
---|---|---|
ATC | B06AC02 | BLOOD AND BLOOD FORMING ORGANS OTHER HEMATOLOGICAL AGENTS OTHER HEMATOLOGICAL AGENTS Drugs used in hereditary angioedema |
MeSH PA | D000700 | Analgesics |
MeSH PA | D018712 | Analgesics, Non-Narcotic |
MeSH PA | D000893 | Anti-Inflammatory Agents |
MeSH PA | D000894 | Anti-Inflammatory Agents, Non-Steroidal |
MeSH PA | D018501 | Antirheumatic Agents |
MeSH PA | D065094 | Bradykinin B2 Receptor Antagonists |
MeSH PA | D065168 | Bradykinin Receptor Antagonists |
MeSH PA | D051056 | Complement Inactivating Agents |
MeSH PA | D007155 | Immunologic Factors |
MeSH PA | D007166 | Immunosuppressive Agents |
MeSH PA | D018373 | Peripheral Nervous System Agents |
MeSH PA | D018689 | Sensory System Agents |
FDA MoA | N0000182964 | Bradykinin B2 Receptor Antagonists |
FDA EPC | N0000182965 | Bradykinin B2 Receptor Antagonist |
CHEBI has role | CHEBI:35530 | beta-adrenergic blockers |
CHEBI has role | CHEBI:63175 | peptidomimetics |
CHEBI has role | CHEBI:68557 | bradykinin receptor antagonists |
Disease | Relation | SNOMED_ID | DOID |
---|---|---|---|
Hereditary angioneurotic edema | indication | 82966003 | DOID:14735 |
None
None
Dissociation level | Dissociation constant | Type (acidic/basic) |
---|---|---|
pKa1 | 3.3 | acidic |
pKa2 | 13.85 | acidic |
pKa3 | 12.18 | Basic |
pKa4 | 10.88 | Basic |
pKa5 | 10.16 | Basic |
pKa6 | 7.56 | Basic |
None
None
Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
---|---|---|---|---|---|---|---|---|---|
B2 bradykinin receptor | GPCR | ANTAGONIST | Ki | 10.22 | CHEMBL | CHEMBL | |||
B1 bradykinin receptor | GPCR | ANTAGONIST | Ki | 7 | IUPHAR | ||||
B2 bradykinin receptor | GPCR | Ki | 10.11 | CHEMBL | |||||
B2 bradykinin receptor | GPCR | Ki | 9.96 | CHEMBL | |||||
B2 bradykinin receptor | GPCR | ANTAGONIST | Ki | 9.60 | IUPHAR | ||||
B1 bradykinin receptor | GPCR | ANTAGONIST | Ki | 6.40 | IUPHAR |
ID | Source |
---|---|
4031108 | VUID |
N0000183562 | NUI |
D04492 | KEGG_DRUG |
138614-30-9 | SECONDARY_CAS_RN |
4031108 | VANDF |
C0246269 | UMLSCUI |
CHEBI:68556 | CHEBI |
CHEMBL2028850 | ChEMBL_ID |
CHEMBL2028852 | ChEMBL_ID |
DB06196 | DRUGBANK_ID |
C065679 | MESH_SUPPLEMENTAL_RECORD_UI |
667 | IUPHAR_LIGAND_ID |
6922 | INN_ID |
7PG89G35Q7 | UNII |
6918173 | PUBCHEM_CID |
1148138 | RXNORM |
160761 | MMSL |
320534 | MMSL |
d07393 | MMSL |
012894 | NDDF |
012895 | NDDF |
703834005 | SNOMEDCT_US |
703835006 | SNOMEDCT_US |
715582002 | SNOMEDCT_US |
Product | Category | Ingredients | NDC | Form | Quantity | Route | Marketing | Label |
---|---|---|---|---|---|---|---|---|
Icatibant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 0093-3066 | INJECTION, SOLUTION | 10 mg | SUBCUTANEOUS | ANDA | 27 sections |
Icatibant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24201-207 | INJECTION, SOLUTION | 30 mg | SUBCUTANEOUS | ANDA | 29 sections |
Icatibant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 24201-207 | INJECTION, SOLUTION | 30 mg | SUBCUTANEOUS | ANDA | 29 sections |
Icatibant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54092-135 | INJECTION, SOLUTION | 30 mg | SUBCUTANEOUS | NDA authorized generic | 34 sections |
Firazyr | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54092-702 | INJECTION, SOLUTION | 30 mg | SUBCUTANEOUS | NDA | 34 sections |
Firazyr | HUMAN PRESCRIPTION DRUG LABEL | 1 | 54092-702 | INJECTION, SOLUTION | 30 mg | SUBCUTANEOUS | NDA | 34 sections |
ICATIBANT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 60505-6214 | INJECTION, SOLUTION | 30 mg | SUBCUTANEOUS | ANDA | 29 sections |
Icatibant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 63323-574 | INJECTION, SOLUTION | 10 mg | SUBCUTANEOUS | ANDA | 29 sections |
Icatibant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68462-828 | INJECTION, SOLUTION | 30 mg | SUBCUTANEOUS | ANDA | 29 sections |
Icatibant | HUMAN PRESCRIPTION DRUG LABEL | 1 | 68462-828 | INJECTION, SOLUTION | 30 mg | SUBCUTANEOUS | ANDA | 29 sections |
ICATIBANT | HUMAN PRESCRIPTION DRUG LABEL | 1 | 69097-664 | INJECTION | 30 mg | SUBCUTANEOUS | ANDA | 25 sections |
SAJAZIR | HUMAN PRESCRIPTION DRUG LABEL | 1 | 70709-013 | INJECTION | 30 mg | SUBCUTANEOUS | ANDA | 25 sections |
Icatibant | Human Prescription Drug Label | 1 | 71225-114 | INJECTION | 30 mg | SUBCUTANEOUS | ANDA | 26 sections |